Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

Alzheimer's and Dementia

Volumn 12, Issue 3, 2016, Pages 292-323

  Dubois, Bruno ^a   Hampel, Harald ^a,b   Feldman, Howard H ^c   Scheltens, Philip ^d   Aisen, Paul ^e   Andrieu, Sandrine ^f   Bakardjian, Hovagim ^g   Benali, Habib ^a   Bertram, Lars ^h,i   Blennow, Kaj ^j   Broich, Karl ^k   Cavedo, Enrica ^b,l   Crutch, Sebastian ^m   Dartigues, Jean François ⁿ   Duyckaerts, Charles ^o   Epelbaum, Stéphane ^a   Frisoni, Giovanni B ^l,p   Gauthier, Serge ^q   Genthon, Remy ^a   Gouw, Alida A ^f,r   Habert, Marie Odile ^a,o   Holtzman, David M ^s   Kivipelto, Miia ^t,u   Lista, Simone ^b   Molinuevo, José Luis ^v,w   O'Bryant, Sid E ^x   Rabinovici, Gil D ^y   Rowe, Christopher ^z   Salloway, Stephen ^aa   Schneider, Lon S ^ab   Sperling, Reisa ^ac,ad   Teichmann, Marc ^a   Carrillo, Maria C ^ae   Cummings, Jeffrey ^af   Jack, Cliff R ^ag   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b AXA   (France)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITÉ PAUL SABATIER   (France)

^g Institut de Recherche Translationnelle en Neurosciences ICM A IHU   (France)

^h UNIVERSITY OF LÜBECK   (Germany)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^k FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^l IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ UNIVERSITÉ DE BORDEAUX   (France)

^o SORBONNE UNIVERSITÉ   (France)

^p UNIVERSITY OF GENEVA   (Switzerland)

^q MCGILL UNIVERSITY   (Canada)

^r VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^s WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^u UNIVERSITY OF EASTERN FINLAND   (Finland)

^v HOSPITAL CLÍNIC   (Spain)

^w Barcelonaßeta Brain Research Center   (Spain)

^x UNIVERSITY OF NORTH TEXAS   (United States)

^y UNIVERSITY OF CALIFORNIA   (United States)

^z UNIVERSITY OF MELBOURNE   (Australia)

^aa BROWN UNIVERSITY   (United States)

^ab UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^ac BRIGHAM AND WOMEN S HOSPITAL   (United States)

^ad MASSACHUSETTS GENERAL HOSPITAL   (United States)

^ae ALZHEIMER'S ASSOCIATION   (United States)

^af CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^ag MAYO CLINIC   (United States)

more..

Author keywords

Alzheimer's disease; Amyloid PET; Asymptomatic; Biomarkers; Blood biomarkers; CSF biomarkers; Diagnostic criteria; Genetics; MRI; Pathophysiology; Preclinical; Tau PET

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CELECOXIB; CRENEZUMAB; ESTROGEN; FATTY ACID; GANTENERUMAB; GEMFIBROZIL; GINKGO BILOBA EXTRACT; JNJ 54861911; NAPROXEN; OMEGA 2 FATTY ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; SIMVASTATIN; SOLANEZUMAB; TAU PROTEIN; THIOCTIC ACID; UNCLASSIFIED DRUG;

AEROBIC EXERCISE; AGE DISTRIBUTION; ALZHEIMER DISEASE; ASYMPTOMATIC DISEASE; BRAIN RADIOGRAPHY; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COGNITIVE DEFECT; CONNECTOME; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; ELECTROENCEPHALOGRAPHY; GENETIC RISK; HUMAN; LIFESTYLE; MUSCLE STRETCHING; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAXATION TRAINING; RESEARCH ETHICS; RESISTANCE TRAINING; REVIEW; RISK ASSESSMENT; SCREENING; SENILE PLAQUE; STANDARDIZATION; STUDY DESIGN; TAUOPATHY; ANIMAL; BRAIN; DIAGNOSTIC IMAGING; GENETICS; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE PROGRESSION; HUMANS;

EID: 84962325429     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.02.002     Document Type: Review

References (298)

1. B.M. Hubbard, G.W. Fenton, and J.M. Anderson A quantitative histological study of early clinical and preclinical Alzheimer's disease Neuropathol Appl Neurobiol 16 1990 111 121
2. H. Hampel, R. Frank, K. Broich, S.J. Teipel, R.G. Katz, J. Hardy, and et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Nat Rev Drug Discov 9 2010 560 574
3. R.J. Bateman, C. Xiong, T.L. Benzinger, A.M. Fagan, A. Goate, N.C. Fox, and et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease N Engl J Med 367 2012 795 804
4. A.M. Fagan, C. Xiong, M.S. Jasielec, R.J. Bateman, A.M. Goate, T.L. Benzinger, and et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease Sci Transl Med 6 2014 226ra30
5. P. Buchhave, L. Minthon, H. Zetterberg, A.K. Wallin, K. Blennow, and O. Hansson Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia Arch Gen Psychiatry 69 2012 98 106
6. O. Delaere, U. Mennen, W. Van Heerden, E. Raubenheimer, A.M. Wiese, and D. Boomker Side-effects of rinsing fluids on the rat femoral artery. A histological and electron microscopic study J Hand Surg Br 22 1997 568 573
7. C.R. Jack Jr., P. Vemuri, H.J. Wiste, S.D. Weigand, P.S. Aisen, J.Q. Trojanowski, and et al. Evidence for ordering of Alzheimer disease biomarkers Arch Neurol 68 2011 1526 1535
8. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, P. Barberger-Gateau, and et al. Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
9. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, M.W. Weiner, and et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
10. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, A.M. Fagan, and et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
11. B. Dubois, H.H. Feldman, C. Jacova, H. Hampel, J.L. Molinuevo, K. Blennow, and et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria Lancet Neurol 13 2014 614 629
12. C.R. Jack Jr., and D.M. Holtzman Biomarker modeling of Alzheimer's disease Neuron 80 2013 1347 1358
13. C.R. Jack Jr., H.J. Wiste, S.D. Weigand, D.S. Knopman, V. Lowe, P. Vemuri, and et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity Neurology 81 2013 1732 1740
14. J. Brettschneider, K. Del Tredici, V.M. Lee, and J.Q. Trojanowski Spreading of pathology in neurodegenerative diseases: a focus on human studies Nat Rev Neurosci 16 2015 109 120
15. G. Heilbronner, Y.S. Eisele, F. Langer, S.A. Kaeser, R. Novotny, A. Nagarathinam, and et al. Seeded strain-like transmission of beta-amyloid morphotypes in APP transgenic mice EMBO Rep 14 2013 1017 1022
16. P.T. Nelson, E. Head, F.A. Schmitt, P.R. Davis, J.H. Neltner, G.A. Jicha, and et al. Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies Acta Neuropathol 121 2011 571 587
17. L. Bertram, and R.E. Tanzi The genetics of Alzheimer's disease Prog Mol Biol Transl Sci 107 2012 79 100
18. L. Jones, P.A. Holmans, M.L. Hamshere, D. Harold, V. Moskvina, D. Ivanov, and et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease PLoS One 5 2010 e13950
19. International Genomics of Alzheimer's Disease Consortium Convergent genetic and expression data implicate immunity in Alzheimer's disease Alzheimers Dement 11 2015 658 671
20. S. Norton, F.E. Matthews, D.E. Barnes, K. Yaffe, and C. Brayne Potential for primary prevention of Alzheimer's disease: An analysis of population-based data Lancet Neurol 13 2014 788 794
21. S.J. Vos, C. Xiong, P.J. Visser, M.S. Jasielec, J. Hassenstab, E.A. Grant, and et al. Preclinical Alzheimer's disease and its outcome: A longitudinal cohort study Lancet Neurol 12 2013 957 965
22. K.A. Johnson, A. Schultz, R.A. Betensky, J.A. Becker, J. Sepulcre, D. Rentz, and et al. Tau PET imaging in aging and early Alzheimer's disease Ann Neurol 79 2016 110 119
23. C.R. Jack Jr., M.S. Albert, D.S. Knopman, G.M. McKhann, R.A. Sperling, M.C. Carrillo, and et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 257 262
24. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, P.S. Aisen, and et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol 12 2013 207 216
25. P. Delaere, Y. He, G. Fayet, C. Duyckaerts, and J.J. Hauw Beta A4 deposits are constant in the brain of the oldest old: An immunocytochemical study of 20 French centenarians Neurobiol Aging 14 1993 191 194
26. E. Cavedo, M. Pievani, M. Boccardi, S. Galluzzi, M. Bocchetta, M. Bonetti, and et al. Medial temporal atrophy in early and late-onset Alzheimer's disease Neurobiol Aging 35 2014 2004 2012
27. Jack CR, Bennett DA, Blennow K, Carrillo M, Feldman H, Frisoni G, et al. Amyloid/tau/neurodegeneration (A/T/N): An unbiased descriptive classification scheme for biomarkers commonly used in Alzheimers disease research. submitted.
28. H. Braak, and K. Del Tredici The pathological process underlying Alzheimer's disease in individuals under thirty Acta Neuropathol 121 2011 171 181
29. C. Duyckaerts Tau pathology in children and young adults: can you still be unconditionally baptist? Acta Neuropathol 121 2011 145 147
30. E.B. Mukaetova-Ladinska, C.R. Harrington, M. Roth, and C.M. Wischik Alterations in tau protein metabolism during normal aging Dementia 7 1996 95 103
31. J.F. Crary, J.Q. Trojanowski, J.A. Schneider, J.F. Abisambra, E.L. Abner, I. Alafuzoff, and et al. Primary age-related tauopathy (PART): A common pathology associated with human aging Acta Neuropathol 128 2014 755 766
32. C. Duyckaerts, H. Braak, J.P. Brion, L. Buee, K. Del Tredici, M. Goedert, and et al. PART is part of Alzheimer disease Acta Neuropathol 129 2015 749 756
33. V.L. Villemagne, K.E. Pike, G. Chetelat, K.A. Ellis, R.S. Mulligan, P. Bourgeat, and et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease Ann Neurol 69 2011 181 192
34. H. Braak, and E. Braak Frequency of stages of Alzheimer-related lesions in different age categories Neurobiol Aging 18 1997 351 357
35. Z.S. Khachaturian Diagnosis of Alzheimer's disease Arch Neurol 42 1985 1097 1105
36. S.S. Mirra, A. Heyman, D. McKeel, S.M. Sumi, B.J. Crain, L.M. Brownlee, and et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease Neurology 41 1991 479 486
37. L. Bertram, C.M. Lill, and R.E. Tanzi The genetics of Alzheimer disease: back to the future Neuron 68 2010 270 281
38. C. Holmes, and S. Lovestone The clinical phenotype of familial and sporadic late onset Alzheimer's disease Int J Geriatr Psychiatry 17 2002 146 149
39. D.C. Ryman, N. Acosta-Baena, P.S. Aisen, T. Bird, A. Danek, N.C. Fox, and et al. Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis Neurology 83 2014 253 260
40. M. Haupt, A. Kurz, S. Pollmann, and B. Romero Alzheimer's disease: Identical phenotype of familial and non-familial cases J Neurol 239 1992 248 250
41. L. Marechal, D. Campion, and D. Hannequin Familial forms of Alzheimer's disease Presse Med 32 2003 756 763
42. D. Nochlin, G. van Belle, T.D. Bird, and S.M. Sumi Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer's disease Alzheimer Dis Assoc Disord 7 1993 212 222
43. N.I. Bohnen, D.S. Djang, K. Herholz, Y. Anzai, and S. Minoshima Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature J Nucl Med 53 2012 59 71
44. R.L. Buckner, J. Sepulcre, T. Talukdar, F.M. Krienen, H. Liu, T. Hedden, and et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease J Neurosci 29 2009 1860 1873
45. W. Jagust Amyloid + activation = Alzheimer's? Neuron 63 2009 141 143
46. W.J. Jansen, R. Ossenkoppele, D.L. Knol, B.M. Tijms, P. Scheltens, F.R. Verhey, and et al. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis JAMA 313 2015 1924 1938
47. D.R. Gustafson, I. Skoog, L. Rosengren, H. Zetterberg, and K. Blennow Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women J Neurol Neurosurg Psychiatry 78 2007 461 464
48. A.M. Fagan, C.M. Roe, C. Xiong, M.A. Mintun, J.C. Morris, and D.M. Holtzman Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 64 2007 343 349
49. E. Stomrud, O. Hansson, K. Blennow, L. Minthon, and E. Londos Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly Dement Geriatr Cogn Disord 24 2007 118 124
50. J. Fortea, A. Llado, B. Bosch, A. Antonell, R. Oliva, J.L. Molinuevo, and et al. Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations Neurodegener Dis 8 2011 202 207
51. A.C. van Harten, P.J. Visser, Y.A. Pijnenburg, C.E. Teunissen, M.A. Blankenstein, P. Scheltens, and et al. Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints Alzheimers Dement 9 2013 481 487
52. J. Fortea, R. Sala-Llonch, D. Bartres-Faz, A. Llado, C. Sole-Padulles, B. Bosch, and et al. Cognitively preserved subjects with transitional cerebrospinal fluid ss-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas Biol Psychiatry 70 2011 183 190
53. L. Rami, R. Sala-Llonch, C. Sole-Padulles, J. Fortea, J. Olives, A. Llado, and et al. Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease J Alzheimers Dis 31 2012 517 526
54. C.M. Roe, A.M. Fagan, E.A. Grant, D.M. Holtzman, and J.C. Morris CSF biomarkers of Alzheimer disease: "Noncognitive" outcomes Neurology 81 2013 2028 2031
55. I.A. van Rossum, S.J. Vos, L. Burns, D.L. Knol, P. Scheltens, H. Soininen, and et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology Neurology 79 2012 1809 1816
56. I.A. van Rossum, P.J. Visser, D.L. Knol, W.M. van der Flier, C.E. Teunissen, F. Barkhof, and et al. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease J Alzheimers Dis 29 2012 319 327
57. H. Braak, H. Zetterberg, K. Del Tredici, and K. Blennow Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-beta changes occur before increases of tau in cerebrospinal fluid Acta Neuropathol 126 2013 631 641
58. P.V. Arriagada, J.H. Growdon, E.T. Hedley-Whyte, and B.T. Hyman Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease Neurology 42 1992 631 639
59. H. Braak, and E. Braak Neuropathological stageing of Alzheimer-related changes Acta Neuropathol 82 1991 239 259
60. A.C. van Harten, M.I. Kester, P.J. Visser, M.A. Blankenstein, Y.A. Pijnenburg, W.M. van der Flier, and et al. Tau and p-tau as CSF biomarkers in dementia: A meta-analysis Clin Chem Lab Med 49 2011 353 366
61. K. Buerger, M. Ewers, T. Pirttila, R. Zinkowski, I. Alafuzoff, S.J. Teipel, and et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease Brain 129 2006 3035 3041
62. T. Tapiola, I. Alafuzoff, S.K. Herukka, L. Parkkinen, P. Hartikainen, H. Soininen, and et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch Neurol 66 2009 382 389
63. F.H. Duits, C.E. Teunissen, F.H. Bouwman, P.J. Visser, N. Mattsson, H. Zetterberg, and et al. The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean? Alzheimers Dement 10 2014 713 723.e2
64. M. Ewers, N. Mattsson, L. Minthon, J.L. Molinuevo, A. Antonell, J. Popp, and et al. CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study Alzheimers Dement 11 2015 1306 1315
65. S. Villeneuve, G.D. Rabinovici, B.I. Cohn-Sheehy, C. Madison, N. Ayakta, P.M. Ghosh, and et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: Statistical and pathological evaluation Brain 138 2015 2020 2033
66. M.E. Murray, V.J. Lowe, N.R. Graff-Radford, A.M. Liesinger, A. Cannon, S.A. Przybelski, and et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum Brain 138 2015 1370 1381
67. C.M. Clark, M.J. Pontecorvo, T.G. Beach, B.J. Bedell, R.E. Coleman, P.M. Doraiswamy, and et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: A prospective cohort study Lancet Neurol 11 2012 669 678
68. C. Curtis, J.E. Gamez, U. Singh, C.H. Sadowsky, T. Villena, M.N. Sabbagh, and et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density JAMA Neurol 72 2015 287 294
69. O. Sabri, M.N. Sabbagh, J. Seibyl, H. Barthel, H. Akatsu, Y. Ouchi, and et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study Alzheimers Dement 11 2015 964 974
70. D.R. Thal, T.G. Beach, M. Zanette, K. Heurling, A. Chakrabarty, A. Ismail, and et al. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-beta pathology Alzheimers Dement 11 2015 975 985
71. S.M. Landau, B.A. Thomas, L. Thurfjell, M. Schmidt, R. Margolin, M. Mintun, and et al. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers Eur J Nucl Med Mol Imaging 41 2014 1398 1407
72. W.E. Klunk, R.A. Koeppe, J.C. Price, T.L. Benzinger, M.D. Devous Sr., W.J. Jagust, and et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET Alzheimers Dement 11 2015 1 15.e1-4
73. G.D. Rabinovici, H.J. Rosen, A. Alkalay, J. Kornak, A.J. Furst, N. Agarwal, and et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD Neurology 77 2011 2034 2042
74. L. Thurfjell, J. Lilja, R. Lundqvist, C. Buckley, A. Smith, R. Vandenberghe, and et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: Concordance with visual image reads J Nucl Med 55 2014 1623 1628
75. A.D. Cohen, W. Mowrey, L.A. Weissfeld, H.J. Aizenstein, E. McDade, J.M. Mountz, and et al. Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches Neuroimage 71 2013 207 215
76. S. Schreiber, S.M. Landau, A. Fero, F. Schreiber, W.J. Jagust Alzheimer's Disease Neuroimaging Initiative Comparison of visual and quantitative Florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes JAMA Neurol 72 2015 1183 1190
77. M. Zwan, A. van Harten, R. Ossenkoppele, F. Bouwman, C. Teunissen, S. Adriaanse, and et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort J Alzheimers Dis 41 2014 801 807
78. S. Palmqvist, H. Zetterberg, K. Blennow, S. Vestberg, U. Andreasson, D.J. Brooks, and et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography JAMA Neurol 71 2014 1282 1289
79. S.M. Landau, M. Lu, A.D. Joshi, M. Pontecorvo, M.A. Mintun, J.Q. Trojanowski, and et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid Ann Neurol 74 2013 826 836
80. N. Mattsson, P.S. Insel, M. Donohue, S. Landau, W.J. Jagust, L.M. Shaw, and et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease Brain 138 2015 772 783
81. C.F. Xia, J. Arteaga, G. Chen, U. Gangadharmath, L.F. Gomez, D. Kasi, and et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease Alzheimers Dement 9 2013 666 676
82. N. Okamura, S. Furumoto, R. Harada, T. Tago, T. Yoshikawa, M. Fodero-Tavoletti, and et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease J Nucl Med 54 2013 1420 1427
83. D.T. Chien, S. Bahri, A.K. Szardenings, J.C. Walsh, F. Mu, M.Y. Su, and et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807 J Alzheimers Dis 34 2013 457 468
84. M. Maruyama, H. Shimada, T. Suhara, H. Shinotoh, B. Ji, J. Maeda, and et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls Neuron 79 2013 1094 1108
85. N. Okamura, S. Furumoto, M.T. Fodero-Tavoletti, R.S. Mulligan, R. Harada, P. Yates, and et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET Brain 137 2014 1762 1771
86. R. Ossenkoppele, D.R. Schonhaut, S.L. Baker, J.P. O'Neil, M. Janabi, P.M. Ghosh, and et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy Ann Neurol 77 2015 338 342
87. B.T. Hyman, C.H. Phelps, T.G. Beach, E.H. Bigio, N.J. Cairns, M.C. Carrillo, and et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease Alzheimers Dement 8 2012 1 13
88. M. Bjerke, E. Portelius, L. Minthon, A. Wallin, H. Anckarsater, R. Anckarsater, and et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid Int J Alzheimers Dis 2010 2010
89. H. Vanderstichele, E. Stoops, E. Vanmechelen, and A. Jeromin Potential sources of interference on Abeta immunoassays in biological samples Alzheimers Res Ther 4 2012 39
90. N. Mattsson, U. Andreasson, S. Persson, M.C. Carrillo, S. Collins, S. Chalbot, and et al. CSF biomarker variability in the Alzheimer's Association quality control program Alzheimers Dement 9 2013 251 261
91. M.C. Carrillo, K. Blennow, H. Soares, P. Lewczuk, N. Mattsson, P. Oberoi, and et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium Alzheimers Dement 9 2013 137 140
92. C.E. Teunissen, N.A. Verwey, M.I. Kester, K. van Uffelen, and M.A. Blankenstein Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid beta((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop Int J Alzheimers Dis 2010 2010
93. H. Vanderstichele, M. Bibl, S. Engelborghs, N. Le Bastard, P. Lewczuk, J.L. Molinuevo, and et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative Alzheimers Dement 8 2012 65 73
94. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat Rev Neurol 6 2010 131 144
95. N. Mattsson, and H. Zetterberg What is a certified reference material? Biomark Med 6 2012 369 370
96. N. Mattsson, I. Zegers, U. Andreasson, M. Bjerke, M.A. Blankenstein, R. Bowser, and et al. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid beta42 Biomark Med 6 2012 409 417
97. A. Leinenbach, J. Pannee, T. Dulffer, A. Huber, T. Bittner, U. Andreasson, and et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid Clin Chem 60 2014 987 994
98. T. Bittner, H. Zetterberg, C.E. Teunissen, R.E. Ostlund Jr., M. Militello, U. Andreasson, and et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1-42) in human cerebrospinal fluid Alzheimers Dement 2015
99. K.E. Pike, G. Savage, V.L. Villemagne, S. Ng, S.A. Moss, P. Maruff, and et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease Brain 130 2007 2837 2844
100. M. Wirth, H. Oh, E.C. Mormino, C. Markley, S.M. Landau, and W.J. Jagust The effect of amyloid beta on cognitive decline is modulated by neural integrity in cognitively normal elderly Alzheimers Dement 9 2013 687 698.e1
101. E.C. Mormino, R.A. Betensky, T. Hedden, A.P. Schultz, R.E. Amariglio, D.M. Rentz, and et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals JAMA Neurol 71 2014 1379 1385
102. Y.Y. Lim, P. Maruff, R.H. Pietrzak, D. Ames, K.A. Ellis, K. Harrington, and et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease Brain 137 2014 221 231
103. S.M. Landau, M.A. Mintun, A.D. Joshi, R.A. Koeppe, R.C. Petersen, P.S. Aisen, and et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline Ann Neurol 72 2012 578 586
104. M. Storandt, M.A. Mintun, D. Head, and J.C. Morris Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition Arch Neurol 66 2009 1476 1481
105. R.H. Pietrzak, Y.Y. Lim, D. Ames, K. Harrington, C. Restrepo, R.N. Martins, and et al. Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing Neurobiol Aging 36 2015 1231 1238
106. D.S. Knopman, C.R. Jack Jr., H.J. Wiste, S.D. Weigand, P. Vemuri, V. Lowe, and et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease Neurology 78 2012 1576 1582
107. J.B. Toledo, M.W. Weiner, D.A. Wolk, X. Da, K. Chen, S.E. Arnold, and et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition Acta Neuropathol Commun 2 2014 26
108. Y.Y. Lim, V.L. Villemagne, R.H. Pietrzak, D. Ames, K.A. Ellis, K. Harrington, and et al. APOE epsilon4 moderates amyloid-related memory decline in preclinical Alzheimer's disease Neurobiol Aging 36 2015 1239 1244
109. V.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, O. Salvado, and et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study Lancet Neurol 12 2013 357 367
110. G.A. Jicha, E.L. Abner, F.A. Schmitt, R.J. Kryscio, K.P. Riley, G.E. Cooper, and et al. Preclinical AD Workgroup staging: pathological correlates and potential challenges Neurobiol Aging 33 2012 622.e1 622.e16
111. J.B. Toledo, X. Da, M.W. Weiner, D.A. Wolk, S.X. Xie, S.E. Arnold, and et al. CSF Apo-E levels associate with cognitive decline and MRI changes Acta Neuropathol 127 2014 621 632
112. E.C. Mormino, J.T. Kluth, C.M. Madison, G.D. Rabinovici, S.L. Baker, B.L. Miller, and et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects Brain 132 2009 1310 1323
113. E.C. Mormino, R.A. Betensky, T. Hedden, A.P. Schultz, A. Ward, W. Huijbers, and et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease Neurology 82 2014 1760 1767
114. D.M. Rentz, J.J. Locascio, J.A. Becker, E.K. Moran, E. Eng, R.L. Buckner, and et al. Cognition, reserve, and amyloid deposition in normal aging Ann Neurol 67 2010 353 364
115. C.M. Roe, A.M. Fagan, E.A. Grant, D.S. Marcus, T.L. Benzinger, M.A. Mintun, and et al. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition Arch Neurol 68 2011 1145 1151
116. D. Head, J.M. Bugg, A.M. Goate, A.M. Fagan, M.A. Mintun, T. Benzinger, and et al. Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition Arch Neurol 69 2012 636 643
117. K.Y. Liang, M.A. Mintun, A.M. Fagan, A.M. Goate, J.M. Bugg, D.M. Holtzman, and et al. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults Ann Neurol 68 2010 311 318
118. M. Wirth, C.M. Haase, S. Villeneuve, J. Vogel, and W.J. Jagust Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults Neurobiol Aging 35 2014 1873 1882
119. D.A. Snowdon, L.H. Greiner, J.A. Mortimer, K.P. Riley, P.A. Greiner, and W.R. Markesbery Brain infarction and the clinical expression of Alzheimer disease. The Nun Study JAMA 277 1997 813 817
120. C.R. Jack Jr., H.J. Wiste, S.D. Weigand, D.S. Knopman, P. Vemuri, M.M. Mielke, and et al. Age, Sex, and APOE epsilon4 Effects on Memory, Brain Structure, and beta-Amyloid Across the Adult Life Span JAMA Neurol 72 2015 511 519
121. C.C. Rowe, K.A. Ellis, M. Rimajova, P. Bourgeat, K.E. Pike, G. Jones, and et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 31 2010 1275 1283
122. J.C. Morris, and J.L. Price Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease J Mol Neurosci 17 2001 101 118
123. J.C. Morris, C.M. Roe, C. Xiong, A.M. Fagan, A.M. Goate, D.M. Holtzman, and et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging Ann Neurol 67 2010 122 131
124. C.R. Jack Jr., H.J. Wiste, S.D. Weigand, W.A. Rocca, D.S. Knopman, M.M. Mielke, and et al. Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study Lancet Neurol 13 2014 997 1005
125. G.M. Savva, S.B. Wharton, P.G. Ince, G. Forster, F.E. Matthews, C. Brayne, and et al. Age, neuropathology, and dementia N Engl J Med 360 2009 2302 2309
126. N. Schuff, N. Woerner, L. Boreta, T. Kornfield, L.M. Shaw, J.Q. Trojanowski, and et al. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers Brain 132 2009 1067 1077
127. D. Paternico, S. Galluzzi, V. Drago, L. Bocchio-Chiavetto, R. Zanardini, L. Pedrini, and et al. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults Alzheimers Dement 8 2012 520 527
128. J.T. Yu, L. Tan, and J. Hardy Apolipoprotein E in Alzheimer's disease: an update Annu Rev Neurosci 37 2014 79 100
129. E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, and et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 261 1993 921 923
130. A.M. Saunders, W.J. Strittmatter, D. Schmechel, P.H. George-Hyslop, M.A. Pericak-Vance, S.H. Joo, and et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease Neurology 43 1993 1467 1472
131. L.A. Farrer, L.A. Cupples, J.L. Haines, B. Hyman, W.A. Kukull, R. Mayeux, and et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium JAMA 278 1997 1349 1356
132. G.W. Rebeck, J.S. Reiter, D.K. Strickland, and B.T. Hyman Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions Neuron 11 1993 575 580
133. G. Chetelat, and M. Fouquet Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers Rev Neurol (Paris) 169 2013 729 736
134. V. Leoni The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease Clin Chem Lab Med 49 2011 375 383
135. M. Kivipelto, S. Rovio, T. Ngandu, I. Kareholt, M. Eskelinen, B. Winblad, and et al. Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study J Cell Mol Med 12 2008 2762 2771
136. D. Harold, R. Abraham, P. Hollingworth, R. Sims, A. Gerrish, M.L. Hamshere, and et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease Nat Genet 41 2009 1088 1093
137. G. Bu Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy Nat Rev Neurosci 10 2009 333 344
138. H.M. Schipper Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment Neurobiol Aging 32 2011 778 790
139. S.B. Sando, S. Melquist, A. Cannon, M.L. Hutton, O. Sletvold, I. Saltvedt, and et al. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway BMC Neurol 8 2008 9
140. J.C. Lambert, C.A. Ibrahim-Verbaas, D. Harold, A.C. Naj, R. Sims, C. Bellenguez, and et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease Nat Genet 45 2013 1452 1458
141. B. Imtiaz, A.M. Tolppanen, M. Kivipelto, and H. Soininen Future directions in Alzheimer's disease from risk factors to prevention Biochem Pharmacol 88 2014 661 670
142. K. Deckers, M.P. van Boxtel, O.J. Schiepers, M. de Vugt, J.L. Munoz Sanchez, K.J. Anstey, and et al. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies Int J Geriatr Psychiatry 30 2015 234 246
143. P. Vemuri, T.G. Lesnick, S.A. Przybelski, D.S. Knopman, G.M. Preboske, K. Kantarci, and et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly Brain 138 2015 761 771
144. F.E. Matthews, A. Arthur, L.E. Barnes, J. Bond, C. Jagger, L. Robinson, and et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II Lancet 382 2013 1405 1412
145. C. Qiu, E. von Strauss, L. Backman, B. Winblad, and L. Fratiglioni Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden Neurology 80 2013 1888 1894
146. N.D. Barnard, A.I. Bush, A. Ceccarelli, J. Cooper, C.A. de Jager, K.I. Erickson, and et al. Dietary and lifestyle guidelines for the prevention of Alzheimer's disease Neurobiol Aging 35 Suppl 2 2014 S74 S78
147. A. Solomon, F. Mangialasche, E. Richard, S. Andrieu, D.A. Bennett, M. Breteler, and et al. Advances in the prevention of Alzheimer's disease and dementia J Intern Med 275 2014 229 250
148. T. Ngandu, J. Lehtisalo, A. Solomon, E. Levalahti, S. Ahtiluoto, R. Antikainen, and et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial Lancet 385 2015 2255 2263
149. D.C. Matthews, M. Davies, J. Murray, S. Williams, W.H. Tsui, Y. Li, and et al. Physical Activity, Mediterranean Diet and Biomarkers-Assessed Risk of Alzheimer's: A Multi-Modality Brain Imaging Study Adv J Mol Imaging 4 2014 43 57
150. K.I. Erickson, M.W. Voss, R.S. Prakash, C. Basak, A. Szabo, L. Chaddock, and et al. Exercise training increases size of hippocampus and improves memory Proc Natl Acad Sci U S A 108 2011 3017 3022
151. O.C. Okonkwo, S.A. Schultz, J.M. Oh, J. Larson, D. Edwards, D. Cook, and et al. Physical activity attenuates age-related biomarker alterations in preclinical AD Neurology 83 2014 1753 1760
152. L. Mosconi, J. Murray, W.H. Tsui, Y. Li, M. Davies, S. Williams, and et al. Mediterranean Diet and Magnetic Resonance Imaging-Assessed Brain Atrophy in Cognitively Normal Individuals at Risk for Alzheimer's Disease J Prev Alzheimers Dis 1 2014 23 32
153. S.M. Landau, S.M. Marks, E.C. Mormino, G.D. Rabinovici, H. Oh, J.P. O'Neil, and et al. Association of lifetime cognitive engagement and low beta-amyloid deposition Arch Neurol 69 2012 623 629
154. Y. Stern Cognitive reserve in ageing and Alzheimer's disease Lancet Neurol 11 2012 1006 1012
155. N. Scarmeas, G. Levy, M.X. Tang, J. Manly, and Y. Stern Influence of leisure activity on the incidence of Alzheimer's disease Neurology 57 2001 2236 2242
156. R.S. Wilson Elderly women with larger social networks are less likely to develop dementia Evid Based Ment Health 12 2009 22
157. M.J. Valenzuela, and P. Sachdev Brain reserve and dementia: a systematic review Psychol Med 36 2006 441 454
158. Y. Suchy, M.L. Kraybill, and E. Franchow Instrumental activities of daily living among community-dwelling older adults: discrepancies between self-report and performance are mediated by cognitive reserve J Clin Exp Neuropsychol 33 2011 92 100
159. R.Y. Lo, W.J. Jagust Alzheimer's Disease Neuroimaging Initiative Effect of cognitive reserve markers on Alzheimer pathologic progression Alzheimer Dis Assoc Disord 27 2013 343 350
160. T. Jonsson, J.K. Atwal, S. Steinberg, J. Snaedal, P.V. Jonsson, S. Bjornsson, and et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline Nature 488 2012 96 99
161. B.A. Ally, G.E. Jones, J.A. Cole, and A.E. Budson The P300 component in patients with Alzheimer's disease and their biological children Biol Psychol 72 2006 180 187
162. R. Sperling, S. Salloway, D.J. Brooks, D. Tampieri, J. Barakos, N.C. Fox, and et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis Lancet Neurol 11 2012 241 249
163. M.C. Donohue, R.A. Sperling, D.P. Salmon, D.M. Rentz, R. Raman, R.G. Thomas, and et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline JAMA Neurol 71 2014 961 970
164. R.E. Amariglio, M.C. Donohue, G.A. Marshall, D.M. Rentz, D.P. Salmon, S.H. Ferris, and et al. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument JAMA Neurol 72 2015 446 454
165. R.A. Sperling, D.M. Rentz, K.A. Johnson, J. Karlawish, M. Donohue, D.P. Salmon, and et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 6 2014 228fs13
166. M.C. Donohue, A.C. Gamst, R.G. Thomas, R. Xu, L. Beckett, R.C. Petersen, and et al. The relative efficiency of time-to-threshold and rate of change in longitudinal data Contemp Clin Trials 32 2011 685 693
167. S.B. Martin, C.D. Smith, H.R. Collins, F.A. Schmitt, and B.T. Gold Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment Neurobiol Aging 31 2010 1099 1106
168. L.G. Apostolova, L. Mosconi, P.M. Thompson, A.E. Green, K.S. Hwang, A. Ramirez, and et al. Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal Neurobiol Aging 31 2010 1077 1088
169. V. Dore, V.L. Villemagne, P. Bourgeat, J. Fripp, O. Acosta, G. Chetelat, and et al. Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease JAMA Neurol 70 2013 903 911
170. R.S. Desikan, M.R. Sabuncu, N.J. Schmansky, M. Reuter, H.J. Cabral, C.P. Hess, and et al. Selective disruption of the cerebral neocortex in Alzheimer's disease PLoS One 5 2010 e12853
171. C.D. Smith, H. Chebrolu, D.R. Wekstein, F.A. Schmitt, G.A. Jicha, G. Cooper, and et al. Brain structural alterations before mild cognitive impairment Neurology 68 2007 1268 1273
172. S. Burgmans, M.P. van Boxtel, F. Smeets, E.F. Vuurman, E.H. Gronenschild, F.R. Verhey, and et al. Prefrontal cortex atrophy predicts dementia over a six-year period Neurobiol Aging 30 2009 1413 1419
173. M.J. Lazarczyk, P.R. Hof, C. Bouras, and P. Giannakopoulos Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals BMC Med 10 2012 127
174. A. Rizk-Jackson, P. Insel, R. Petersen, P. Aisen, C. Jack, and M. Weiner Early indications of future cognitive decline: stable versus declining controls PLoS One 8 2013 e74062
175. M. Ewers, M. Brendel, A. Rizk-Jackson, A. Rominger, P. Bartenstein, N. Schuff, and et al. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects Neuroimage Clin 4 2014 45 52
176. P.S. Aisen, R.C. Petersen, M.C. Donohue, A. Gamst, R. Raman, R.G. Thomas, and et al. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans Alzheimers Dement 6 2010 239 246
177. M.D. Greicius, G. Srivastava, A.L. Reiss, and V. Menon Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI Proc Natl Acad Sci U S A 101 2004 4637 4642
178. C. Sorg, V. Riedl, M. Muhlau, V.D. Calhoun, T. Eichele, L. Laer, and et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease Proc Natl Acad Sci U S A 104 2007 18760 18765
179. D. Zhang, Y. Wang, L. Zhou, H. Yuan, D. Shen Alzheimer's Disease Neuroimaging Initiative Multimodal classification of Alzheimer's disease and mild cognitive impairment Neuroimage 55 2011 856 867
180. S.L. Miller, K. Celone, K. DePeau, E. Diamond, B.C. Dickerson, D. Rentz, and et al. Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation Proc Natl Acad Sci U S A 105 2008 2181 2186
181. W.W. Seeley, R.K. Crawford, J. Zhou, B.L. Miller, and M.D. Greicius Neurodegenerative diseases target large-scale human brain networks Neuron 62 2009 42 52
182. P.J. Toussaint, S. Maiz, D. Coynel, J. Doyon, A. Messe, L.C. de Souza, and et al. Characteristics of the default mode functional connectivity in normal ageing and Alzheimer's disease using resting state fMRI with a combined approach of entropy-based and graph theoretical measurements Neuroimage 101 2014 778 786
183. R.L. Buckner, A.Z. Snyder, B.J. Shannon, G. LaRossa, R. Sachs, A.F. Fotenos, and et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory J Neurosci 25 2005 7709 7717
184. M. Pihlajamaki, and R.A. Sperling Functional MRI assessment of task-induced deactivation of the default mode network in Alzheimer's disease and at-risk older individuals Behav Neurol 21 2009 77 91
185. E.C. van Straaten, P. Scheltens, A.A. Gouw, and C.J. Stam Eyes-closed task-free electroencephalography in clinical trials for Alzheimer's disease: an emerging method based upon brain dynamics Alzheimers Res Ther 6 2014 86
186. E.J. Golob, J.M. Ringman, R. Irimajiri, S. Bright, B. Schaffer, L.D. Medina, and et al. Cortical event-related potentials in preclinical familial Alzheimer disease Neurology 73 2009 1649 1655
187. Y.T. Quiroz, B.A. Ally, K. Celone, J. McKeever, A.L. Ruiz-Rizzo, F. Lopera, and et al. Event-related potential markers of brain changes in preclinical familial Alzheimer disease Neurology 77 2011 469 475
188. J.F. Alonso, J. Poza, M.A. Mananas, S. Romero, A. Fernandez, and R. Hornero MEG connectivity analysis in patients with Alzheimer's disease using cross mutual information and spectral coherence Ann Biomed Eng 39 2011 524 536
189. R. Bajo, F. Maestu, A. Nevado, M. Sancho, R. Gutierrez, P. Campo, and et al. Functional connectivity in mild cognitive impairment during a memory task: implications for the disconnection hypothesis J Alzheimers Dis 22 2010 183 193
190. F.J. Hsiao, Y.J. Wang, S.H. Yan, W.T. Chen, and Y.Y. Lin Altered oscillation and synchronization of default-mode network activity in mild Alzheimer's disease compared to mild cognitive impairment: an electrophysiological study PLoS One 8 2013 e68792
191. C. Babiloni, R. Lizio, N. Marzano, P. Capotosto, A. Soricelli, A.I. Triggiani, and et al. Brain neural synchronization and functional coupling in Alzheimer's disease as revealed by resting state EEG rhythms Int J Psychophysiol 2015
192. C.J. Stam, B.F. Jones, I. Manshanden, A.M. van Cappellen van Walsum, T. Montez, J.P. Verbunt, and et al. Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer's disease Neuroimage 32 2006 1335 1344
193. M.M. Engels, C.J. Stam, W.M. van der Flier, P. Scheltens, H. de Waal, and E.C. van Straaten Declining functional connectivity and changing hub locations in Alzheimer's disease: an EEG study BMC Neurol 15 2015 145
194. H. Amieva, H. Mokri, M. Le Goff, C. Meillon, H. Jacqmin-Gadda, A. Foubert-Samier, and et al. Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline Brain 137 2014 1167 1175
195. J. Henry, and J.R. Crawford A meta-analytic review of verbal fluency deficits in depression J Clin Exp Neuropsychol 27 2005 78 101
196. L.L. Beheydt, D. Schrijvers, L. Docx, F. Bouckaert, W. Hulstijn, and B. Sabbe Psychomotor retardation in elderly untreated depressed patients Front Psychiatry 5 2014 196
197. R.J. van Holst, and T. Schilt Drug-related decrease in neuropsychological functions of abstinent drug users Curr Drug Abuse Rev 4 2011 42 56
198. D.P. Koster, C.I. Higginson, E.E. MacDougall, V.L. Wheelock, and K.A. Sigvardt Subjective Cognitive Complaints in Parkinson Disease Without Dementia: A Preliminary Study Appl Neuropsychol Adult 22 2015 287 292
199. K.P. Riley, G.A. Jicha, D. Davis, E.L. Abner, G.E. Cooper, N. Stiles, and et al. Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition J Alzheimers Dis 25 2011 707 717
200. T. Hedden, H. Oh, A.P. Younger, and T.A. Patel Meta-analysis of amyloid-cognition relations in cognitively normal older adults Neurology 80 2013 1341 1348
201. H. Amieva, M. Le Goff, X. Millet, J.M. Orgogozo, K. Peres, P. Barberger-Gateau, and et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms Ann Neurol 64 2008 492 498
202. R.F. Buckley, K.A. Ellis, D. Ames, C.C. Rowe, N.T. Lautenschlager, P. Maruff, and et al. Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease Neuropsychology 29 2015 571 581
203. J.M. Ringman, L.J. Liang, Y. Zhou, S. Vangala, E. Teng, S. Kremen, and et al. Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network Brain 138 2015 1036 1045
204. J.B. Langbaum, S.B. Hendrix, N. Ayutyanont, K. Chen, A.S. Fleisher, R.C. Shah, and et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease Alzheimers Dement 10 2014 666 674
205. D.M. Rentz, M.A. Parra Rodriguez, R. Amariglio, Y. Stern, R. Sperling, and S. Ferris Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review Alzheimers Res Ther 5 2013 58
206. C.A. Derby, L.C. Burns, C. Wang, M.J. Katz, M.E. Zimmerman, G. L'Italien, and et al. Screening for predementia AD: time-dependent operating characteristics of episodic memory tests Neurology 80 2013 1307 1314
207. E. Grober, H. Buschke, H. Crystal, S. Bang, and R. Dresner Screening for dementia by memory testing Neurology 38 1988 900 903
208. M. Sarazin, C. Berr, J. De Rotrou, C. Fabrigoule, F. Pasquier, S. Legrain, and et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study Neurology 69 2007 1859 1867
209. M.A. Parra, S. Abrahams, R.H. Logie, L.G. Mendez, F. Lopera, and S. Della Sala Visual short-term memory binding deficits in familial Alzheimer's disease Brain 133 2010 2702 2713
210. R.E. Amariglio, J.A. Becker, J. Carmasin, L.P. Wadsworth, N. Lorius, C. Sullivan, and et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals Neuropsychologia 50 2012 2880 2886
211. G. Chetelat, V.L. Villemagne, P. Bourgeat, K.E. Pike, G. Jones, D. Ames, and et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease Ann Neurol 67 2010 317 324
212. F. Jessen, R.E. Amariglio, M. van Boxtel, M. Breteler, M. Ceccaldi, G. Chetelat, and et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease Alzheimers Dement 10 2014 844 852
213. R. Gallassi, F. Oppi, R. Poda, S. Scortichini, M. Stanzani Maserati, G. Marano, and et al. Are subjective cognitive complaints a risk factor for dementia? Neurol Sci 31 2010 327 336
214. M.M. Mielke, H.J. Wiste, S.D. Weigand, D.S. Knopman, V.J. Lowe, R.O. Roberts, and et al. Indicators of amyloid burden in a population-based study of cognitively normal elderly Neurology 79 2012 1570 1577
215. A.J. Mitchell, H. Beaumont, D. Ferguson, M. Yadegarfar, and B. Stubbs Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis Acta Psychiatr Scand 130 2014 439 451
216. K.E. Pike, K.A. Ellis, V.L. Villemagne, N. Good, G. Chetelat, D. Ames, and et al. Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study Neuropsychologia 49 2011 2384 2390
217. S. Berman, J.P. Lowenthal, J.V. Sorrentino, and A.B. White A safety test for Eastern equine encephalomyelitis vaccine Appl Microbiol 15 1967 968 969
218. V.B. Gupta, R. Sundaram, and R.N. Martins Multiplex biomarkers in blood Alzheimers Res Ther 5 2013 31
219. W.T. Hu, D.M. Holtzman, A.M. Fagan, L.M. Shaw, R. Perrin, S.E. Arnold, and et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease Neurology 79 2012 897 905
220. S.E. O'Bryant, G. Xiao, R. Barber, J. Reisch, R. Doody, T. Fairchild, and et al. A serum protein-based algorithm for the detection of Alzheimer disease Arch Neurol 67 2010 1077 1081
221. J. Doecke, S.M. Laws, N.G. Faux, W. Wilson, S.C. Burnham, C.P. Lam, and et al. Blood-based protein biomarkers for the diagnosis of Alzheimer's disease Arch Neurol 69 2012 1318 1325
222. M. Sattlecker, S.J. Kiddle, S. Newhouse, P. Proitsi, S. Nelson, S. Williams, and et al. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology Alzheimers Dement 10 2014 724 734
223. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
224. S.E. O'Bryant, G. Xiao, R. Barber, R. Huebinger, K. Wilhelmsen, M. Edwards, and et al. A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI PLoS One 6 2011 e28092
225. S.E. O'Bryant, G. Xiao, F. Zhang, M. Edwards, D.C. German, X. Yin, and et al. Validation of a serum screen for alzheimer's disease across assay platforms, species, and tissues J Alzheimers Dis 42 2014 1325 1335
226. S.J. Kiddle, M. Sattlecker, P. Proitsi, A. Simmons, E. Westman, C. Bazenet, and et al. Candidate blood proteome markers of Alzheimer's disease onset and progression: A systematic review and replication study J Alzheimers Dis 38 2014 515 531
227. M. Mapstone, A.K. Cheema, M.S. Fiandaca, X. Zhong, T.R. Mhyre, L.H. Macarthur, and et al. Plasma phospholipids identify antecedent memory impairment in older adults Nature Medicine 20 2014 415 418
228. A. Hye, J. Riddoch-Contreras, A.L. Baird, N.J. Ashton, C. Bazenet, R. Leung, and et al. Plasma proteins predict conversion to dementia from prodromal disease Alzheimers Dement 2014
229. N.R. Graff-Radford, J.E. Crook, J. Lucas, B.F. Boeve, D.S. Knopman, R.J. Ivnik, and et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease Arch Neurol 64 2007 354 362
230. [erratum appears in Arch Neurol. 2007 Sep;64(9):1246]
231. S.C. Burnham, N.G. Faux, W. Wilson, S.M. Laws, D. Ames, J. Bedo, and et al. A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: Results from the AIBL study Mol Psychiatry 19 2014 519 526
232. L.G. Apostolova, K.S. Hwang, D. Avila, D. Elashoff, O. Kohannim, E. Teng, and et al. Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures Neurology 84 2015 729 737
233. S.E. O'Bryant, V. Gupta, K. Henriksen, M. Edwards, A. Jeromin, S. Lista, and et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research Alzheimers Dement 11 2015 549 560
234. R. Mayeux Evaluation and use of diagnostic tests in Alzheimer's disease Neurobiol Aging 19 1998 139 143
235. M. Breteler Mapping out biomarkers for Alzheimer's disease JAMA 305 2011 304 305
236. R. Apweiler, C. Aslanidis, T. Deufel, A. Gerstner, J. Hansen, D. Hochstrasser, and et al. Approaching clinical proteomics: current state and future fields of application in cellular proteomics Cytometry A 75 2009 816 832
237. K. Henriksen, S.E. O'Bryant, H. Hampel, J.Q. Trojanowski, T.J. Montine, A. Jeromin, and et al. The future of blood-based biomarkers for Alzheimer's disease Alzheimers Dement 10 2014 115 131
238. H.M. Snyder, M.C. Carrillo, F. Grodstein, K. Henriksen, A. Jeromin, S. Lovestone, and et al. Developing novel blood-based biomarkers for Alzheimer's disease Alzheimers Dement 10 2014 109 114
239. FDA. Guidance for industry: Alzheimer's disease: developing drugs for the treatment of early stage disease. In: Research CfDEa, editor. Washington, DC 2013.
240. N. Kozauer, and R. Katz Regulatory innovation and drug development for early-stage Alzheimer's disease N Engl J Med 368 2013 1169 1171
241. EMA EMA: Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer s disease and other dementias 2014 London, UK
242. R.J. Kryscio Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point JAMA Neurol 71 2014 947 949
243. APEX. Effect of Aerobic Exercise on Pathophysiology of PreClinical Alzheimer's Disease.
244. A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease 2016
245. S.M. Mills, J. Mallmann, A.M. Santacruz, A. Fuqua, M. Carril, P.S. Aisen, and et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial Rev Neurol (Paris) 169 2013 737 743
246. E.M. Reiman, J.B. Langbaum, A.S. Fleisher, R.J. Caselli, K. Chen, N. Ayutyanont, and et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments J Alzheimers Dis 26 Suppl 3 2011 321 329
247. Takeda Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW) 2016
248. S.A. Cooper, M. Caslake, J. Evans, A. Hassiotis, A. Jahoda, A. McConnachie, and et al. Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial Trials 15 2014 202
249. M. Sano, D. Jacobs, H. Andrews, K. Bell, N. Graff-Radford, J. Lucas, and et al. A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics Clin Trials 5 2008 523 533
250. Group AR Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS Clin Trials 1 2006 e33
251. B. Vellas, N. Coley, P.J. Ousset, G. Berrut, J.F. Dartigues, B. Dubois, and et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial Lancet Neurol 11 2012 851 859
252. E. Richard, E. Van den Heuvel, E.P. Moll van Charante, L. Achthoven, M. Vermeulen, P.J. Bindels, and et al. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress Alzheimer Dis Assoc Disord 23 2009 198 204
253. S. Gillette-Guyonnet, S. Andrieu, T. Dantoine, J.F. Dartigues, J. Touchon, B. Vellas, and et al. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease Alzheimers Dement 5 2009 114 121
254. L.F. ten Brinke, N. Bolandzadeh, L.S. Nagamatsu, C.L. Hsu, J.C. Davis, K. Miran-Khan, and et al. Aerobic exercise increases hippocampal volume in older women with probable mild cognitive impairment: a 6-month randomised controlled trial Br J Sports Med 49 2015 248 254
255. Group AI Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial Contemp Clin Trials 36 2013 555 564
256. Washington Uo Effects of Simvastatin on Biomarkers (SimBio) 2015
257. S.T. DeKosky, A. Fitzpatrick, D.G. Ives, J. Saxton, J. Williamson, O.L. Lopez, and et al. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia Contemp Clin Trials 27 2006 238 253
258. University OHaS Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention 2014
259. Kentucky Uo Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease 2015
260. B. Vellas, M.C. Carrillo, C. Sampaio, H.R. Brashear, E. Siemers, H. Hampel, and et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force Alzheimers Dement 9 2013 438 444
261. C.W. Ritchie, J.L. Molinuevo, L. Truyen, A. Satlin, S. Van der Geyten, S. Lovestone, and et al. Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project Lancet Psychiatry 3 2016 179 186
262. B. Vellas, H. Hampel, M.E. Rouge-Bugat, M. Grundman, S. Andrieu, S. Abu-Shakra, and et al. Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology J Nutr Health Aging 16 2012 339 345
263. B. Vellas, P.S. Aisen, C. Sampaio, M. Carrillo, P. Scheltens, B. Scherrer, and et al. Prevention trials in Alzheimer's disease: an EU-US task force report Prog Neurobiol 95 2011 594 600
264. H. Hampel, S. Lista, S.J. Teipel, F. Garaci, R. Nistico, K. Blennow, and et al. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020 Biochem Pharmacol 88 2014 426 449
265. M.C. Carrillo, H.R. Brashear, V. Logovinsky, J.M. Ryan, H.H. Feldman, E.R. Siemers, and et al. Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease Alzheimers Dement 9 2013 123 131.e1
266. L.S. Schneider, F. Mangialasche, N. Andreasen, H. Feldman, E. Giacobini, R. Jones, and et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 J Intern Med 275 2014 251 283
267. K.R. Peters, B. Lynn Beattie, H.H. Feldman, and J. Illes A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease Prog Neurobiol 110 2013 114 123
268. H. Hampel, G. Wilcock, S. Andrieu, P. Aisen, K. Blennow, K. Broich, and et al. Biomarkers for Alzheimer's disease therapeutic trials Prog Neurobiol 95 2011 579 593
269. D. Holland, L.K. McEvoy, R.S. Desikan, A.M. Dale Alzheimer's Disease Neuroimaging Initiative Enrichment and stratification for predementia Alzheimer disease clinical trials PLoS One 7 2012 e47739
270. E. Richard, S. Andrieu, A. Solomon, F. Mangialasche, S. Ahtiluoto, E.P. Moll van Charante, and et al. Methodological challenges in designing dementia prevention trials - the European Dementia Prevention Initiative (EDPI) J Neurol Sci 322 2012 64 70
271. S.G. Post The Moral Challenge of Alzheimer Disease 1995 The Johns Hopkins University Press Baltimore, MD
272. S. Gauthier, A. Leuzy, E. Racine, and P. Rosa-Neto Diagnosis and management of Alzheimer's disease: past, present and future ethical issues Prog Neurobiol 110 2013 102 113
273. J.D. Grill, J. Karlawish, D. Elashoff, and B.G. Vickrey Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment Alzheimers Dement 9 2013 356 359.e1
274. J.D. Fisk, A.D. Sadovnick, C.A. Cohen, S. Gauthier, J. Dossetor, A. Eberhart, and et al. Ethical guidelines of the Alzheimer Society of Canada Can J Neurol Sci 25 1998 242 248
275. R.J. Caselli, J. Langbaum, G.E. Marchant, R.A. Lindor, K.S. Hunt, B.R. Henslin, and et al. Public perceptions of presymptomatic testing for Alzheimer disease Mayo Clin Proc 89 2014 1389 1396
276. H.M. Schipper Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention Alzheimers Dement 7 2011 e118 e123
277. J.L. Taylor, Q. Kennedy, M.M. Adamson, L.C. Lazzeroni, A. Noda, G.M. Murphy, and et al. Influences of APOE epsilon4 and expertise on performance of older pilots Psychol Aging 26 2011 480 487
278. J. Karlawish Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease Neurology 77 2011 1487 1493
279. MetLife-Foundation MetLife Foundation Alzheimer's Survey: What America Thinks Harris Interactive 2006
280. S. Chao, J.S. Roberts, T.M. Marteau, R. Silliman, L.A. Cupples, and R.C. Green Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study Alzheimer Dis Assoc Disord 22 2008 94 97
281. J.A. Vernarelli, J.S. Roberts, S. Hiraki, C.A. Chen, L.A. Cupples, and R.C. Green Effect of Alzheimer disease genetic risk disclosure on dietary supplement use Am J Clin Nutr 91 2010 1402 1407
282. B. Dubois, S. Epelbaum, A. Santos, F. Di Stefano, A. Julian, A. Michon, and et al. Alzheimer disease: from biomarkers to diagnosis Rev Neurol (Paris) 169 2013 744 751
283. H. Hampel, and S. Lista Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement J Nutr Health Aging 17 2013 54 63
284. H. Hampel, S. Lista, and Z.S. Khachaturian Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot Alzheimers Dement 8 2012 312 336
285. H. Hampel, and S. Lista Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge Nat Rev Neurol 8 2012 598 600
286. L. Bertram, and H. Hampel The role of genetics for biomarker development in neurodegeneration Prog Neurobiol 95 2011 501 504
287. T. Zetzsche, D. Rujescu, J. Hardy, and H. Hampel Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease Expert Rev Mol Diagn 10 2010 667 690
288. S.J. Teipel, M. Grothe, S. Lista, N. Toschi, F.G. Garaci, and H. Hampel Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease Med Clin North Am 97 2013 399 424
289. M. Ewers, R.A. Sperling, W.E. Klunk, M.W. Weiner, and H. Hampel Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia Trends Neurosci 34 2011 430 442
290. S. Lista, S.E. O'Bryant, K. Blennow, B. Dubois, J. Hugon, H. Zetterberg, and et al. Biomarkers in sporadic and familial Alzheimer's Disease J Alzheimers Dis 47 2015 291 317
291. C. Rosen, O. Hansson, K. Blennow, and H. Zetterberg Fluid biomarkers in Alzheimer's disease - current concepts Mol Neurodegener 8 2013 20
292. K. Blennow, H. Zetterberg, and A.M. Fagan Fluid biomarkers in Alzheimer disease Cold Spring Harb Perspect Med 2 2012 a006221
293. H. Hampel, Y. Shen, D.M. Walsh, P. Aisen, L.M. Shaw, H. Zetterberg, and et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease Exp Neurol 223 2010 334 346
294. H. Hampel, K. Blennow, L.M. Shaw, Y.C. Hoessler, H. Zetterberg, and J.Q. Trojanowski Total and phosphorylated tau protein as biological markers of Alzheimer's disease Exp Gerontol 45 2010 30 40
295. M. Edwards, V.H. Balldin, J. Hall, and S. O'Bryant Combining select neuropsychological assessment with blood-based biomarkers to detect mild Alzheimer's disease: a molecular neuropsychology approach J Alzheimers Dis 42 2014 635 640
296. S. Lista, F.G. Garaci, M. Ewers, S. Teipel, H. Zetterberg, K. Blennow, and et al. CSF Abeta1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease Alzheimers Dement 10 2014 381 392
297. K. Broich, M. Weiergraber, and H. Hampel Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements Prog Neurobiol 95 2011 498 500
298. H. Hampel, and S. Lista The rising global tide of cognitive impairment Nat Rev Neurol 2016 10.1038/nrneurol.2015.250